ERBB2 and breast cancer: The intent of this study was to (1) investigate the prevalence of oncotype DX RS testing in women diagnosed with HR+/HER2– breast cancer and its association with mortality across age groups and nodal status, and (2) examine whether testing was associated with adjuvant chemotherapy use across both age and nodal status.